THE PROSPECTIVE STUDY FOR THE MANAGEMENT OF PSORIASIS ARTHRITIS AND RECOVERY OF LESIONS IN TERTIARY CARE HOSPITAL

Abstract

Introduction:  Psoriatic arthritis or PsA or PSA is a heterogeneous, multisystem chronic disease that includes the inflammation and irritation of the synovial tissue, enthuses, skin, and usually seronegative for rheumatoid factor. It causes reduced articular capacity and higher mortality yet additionally to influence patients’ capacity to work and influence their social relations. The main clinical features are spondylitis, inflammatory neck pain, thoracic inflammatory pain, axial symptoms and Sacroiliitis typically can happen unilaterally and become bilaterally before long is atypical side effects among PsA.

Objectives: To find the appropriate treatment of mild, moderate and severe form of psoriatic arthritis.

Materials and Methods: The prospective study with 60 patients were classified according to their severity and then they were given drug treatment. The prognosis of their psoriatic lesion during the follow up was used for evaluation of the efficient drug management.

Result: The study found out that the mild cases were resolved by prescribing corticosteroids and NSAIDs while severe form needed to be given DMARDs and anti-tumor necrosis factor agent along with the previous two drugs. The study has shown that the 100% of the mild cases were resolved due to efficient prescription of appropriate drugs while 45.4% of the severe cases were resolved in severe form due to its severity itself and 2 patients did not receive anti-tumor necrosis factor agent, among which 1 patient did not receive DMARDs as well. Only 11 patients received DMARDs and none of them received anti-tumor necrosis factor agent  in moderate form, which resulted in only 29% of resolution of lesion in moderate cases.

Conclusion: The study has shown that mild cases can be managed by corticosteroids and NSAIDs while moderate cases must be managed ny DMARDs while severe cases should be given the combination therapy of DMARDs and anti-tumor necrosis factor agent.

Keywords: psoriasis, arthritis, dmards